{"id":"nls-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Anxiety"}]},"_chembl":{"chemblId":"CHEMBL539210","moleculeType":"Small molecule","molecularWeight":"745.81"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Orexin neuropeptides regulate sleep-wake cycles and maintain wakefulness through activation of orexin receptors in the brain. By selectively targeting the orexin-2 receptor, NLS-2 enhances wakefulness promotion while potentially minimizing off-target effects associated with dual orexin receptor agonism. This mechanism is designed to treat excessive daytime sleepiness and narcolepsy with improved tolerability.","oneSentence":"NLS-2 is a selective orexin-2 receptor agonist that promotes wakefulness by enhancing neural signaling in brain regions responsible for arousal and alertness.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:27.214Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Narcolepsy type 1 and type 2"},{"name":"Excessive daytime sleepiness"}]},"trialDetails":[{"nctId":"NCT05914194","phase":"PHASE3","title":"A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1","status":"NOT_YET_RECRUITING","sponsor":"NLS Pharmaceutics","startDate":"2024-07-15","conditions":"Narcolepsy Type 1, Narcolepsy With Cataplexy","enrollment":48},{"nctId":"NCT05055024","phase":"PHASE2","title":"An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy","status":"COMPLETED","sponsor":"NLS Pharmaceutics","startDate":"2021-10-26","conditions":"Narcolepsy With Cataplexy, Narcolepsy, Narcolepsy Without Cataplexy","enrollment":52},{"nctId":"NCT04923594","phase":"PHASE2","title":"Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy","status":"COMPLETED","sponsor":"NLS Pharmaceutics","startDate":"2021-09-13","conditions":"Narcolepsy, Excessive Daytime Sleepiness, Cataplexy Narcolepsy","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["mazindol extended-release (ER), mazindol controlled-release (CR)"],"phase":"phase_3","status":"active","brandName":"NLS-2","genericName":"NLS-2","companyName":"NLS Pharmaceutics","companyId":"nls-pharmaceutics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NLS-2 is a selective orexin-2 receptor agonist that promotes wakefulness by enhancing neural signaling in brain regions responsible for arousal and alertness. Used for Narcolepsy type 1 and type 2, Excessive daytime sleepiness.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}